The new test uses advanced genomics-based technology to help physicians determine a tumor’s origin in order to optimize cancer-specific treatment. The study will evaluate the test’s ability to impact diagnosis for cancer patients with hard-to-identify tumors, with test samples processed at the Stanford University School of Medicine’s laboratory.
The Pathwork Tissue of Origin Test measures the expression of more than 1,500 genes to compare a tumor’s gene expression profile to those of 15 known tissues, representing more than 60 morphologies, and to provide a report with an objective, probability-based score for each potential tissue. This helps physicians rule in and rule out potential tissue types.
Deborah Neff, Pathwork Diagnostic’s president and CEO, said: “Our test is available as a service through our CLIA-certified laboratory so that physicians outside of Stanford University can have specimens processed and clinical results provided. Additionally, we are actively working to obtain FDA clearance so that we can offer a diagnostic kit directly to clinical laboratories at major medical centers.”